Tackling underdiagnosis of Large Artery Giant Cell Arteritis: a prevalence and phenotype study.

Tackling underdiagnosis of Large Artery Giant Cell Arteritis: a prevalence and phenotype study. - Prevalence of large artery giant cell arteritis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35072

Enrollment

100

Registered

2010-08-12

Start date

2010-09-09

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

giant cell arteritis large vessel vasculitis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Giant cell arteritis according to the 1990 ACR classification critieria, or elevated ESR on 2 separate occasions with a time interval of at least 4 weeks, the elevated ESR is not explained by a chest radiograph, abdominal ultrasound or blood tests (including paraprotein testing)

Exclusion criteria

Exclusion criteria: The use of corticosteroids or any other systemic immunosuppresant for more than 24 hours at the time of PET-CT scanning. Inability to understand or unwillingness to provide informed consent. A plasma glucose level >11 mmol/l at the time of PET-CT scanning.

Design outcomes

Primary

Measure	Time frame
Prevalence of large-vessel-vasculitis in patients with temporal arteritis or unexplained prolonged inflammatory response. Diagnostic utility of PET/low-dose-CT in patients with an unexplained prolonged inflammatory response.	—

Secondary

Measure	Time frame
Association between large-vessel-vasculitis and clinical/biochemical parameters. Association between large-vessel-vasculitis and inflammation score of temporal artery biopsy. Sensitivity and specificity of temporal artery biopsy for large-vessel-vasculitis. Association between FDG-uptake and vessel wall morphology/lumen morphology.	—

Countries

Netherlands

Outcome results